News Posts List
Uplifting Athletes takes aim at rare diseases
06/25/2013
When Scott Shirley launched Uplifting Athletes in 2007, the nonprofit operated in the basement of his mother’s Enola home.
Gene mutations may cause aggressive renal cancer
06/24/2013
Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer...
Poll: Will the Affordable Care Act help or hurt people living with kidney cancer?
06/22/2013
We recently polled the more than 67,000 members of our Facebook community about the Affordable Care Act.
Long-Term Care Insurance Market Collapses
06/20/2013
WSJ: Employee Benefit Research Institute CEO Dallas Salisbury says health care costs - not income - is the ticking time bomb for American retirees, saying "the long term care private insurance market is essentially collapsing."
Kaiser Poll: Unfavorable Views of ACA (Obamacare) Outnumber Favorable
06/20/2013
Unfavorable views of the law still outnumber favorable ones by a substantial margin.
Medicare Administrator Issues Final Local Coverage Determination for Rosetta Cancer Origin Test
06/14/2013
microRNA assay determined reasonable and necessary for providing an important niche in pathologic diagnoses of Cancer of Unknown Primary.
How Do We Know Which Cancer Therapies Really Work?
06/13/2013
The FDA has approved more than 30 molecularly targeted agents in cancer in recent years, including prominent examples such as trastuzumab for breast cancer, sunitinib for renal cell cancer and bevacizumab for colorectal, non-small cell lung and renal cell cancers.
Threshold announces encouraging data from Phase I/II cancer trials
06/13/2013
Threshold Pharmaceuticals, Inc., a biotechnology company, has announced data from two ongoing Phase I/II trials evaluating TH-302, an investigational hypoxia-targeted drug, in patients with relapsed/refractory multiple myeloma and gastrointestinal stromal tumors and renal cell carcinoma.
Argos Therapeutics Announces US And Global Expansion For Ongoing Pivotal Phase 3 ADAPT Study For Personalized Immunotherapy
06/13/2013
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, has announced it has expanded its ADAPT Phase 3 clinical study for AGS-003 to additional top cancer centers in the United States, Canada and will soon be expanding into Europe and Israel.
News Feed